Junaxo is a privately-held Canadian drug development company specializing in repurposing compounds for the treatment of neurological disorders, currently with an emphasis on Parkinson’s disease and amyotrophic lateral sclerosis. 


Our current programs are based around compounds that are clinical trial ready and targets that have demonstrated proof-of-concept efficacy in the best pre-clinical models available.



ABOUT Junaxo 

The Founders of Junaxo have internationally-renowned expertise in developing compounds for the treatment of neurodegenerative disorders, specifically for Parkinson’s disease and related disorders. To date, we have identified, evaluated and in-licensed, three assets; two products for the treatment of Parkinson’s disease and one product for the treatment of amyotrophic lateral sclerosis.


Junaxo uses the virtual drug development model which allows us to efficiently manage our resources and operate with a very low burn rate. We also focus on developing compounds for Orphan Diseases or Medical Foods allowing us to reach early revenue streams. Core management experience is retained in-house enabling Junaxo to develop effective strategies and oversee outsourced research.